Neurology News

Use of a genetic risk test for patients considering immunosuppressive therapies associated with development of progressive multifocal leukoencephalopathy may help reduce incidence of disease, researchers reported in Frontiers in Neurology.

An estimated 55.8 million patients presented to U.S. emergency departments from 2016 to 2019 with a neurological complaint as the primary reason for their visit, researchers reported in JAMA Neurology.

A higher locus of control at work and home was associated with reduced psychosocial stress and lower odds of acute stroke, researchers reported in JAMA Network Open.

Imbrium Therapeutics LP, a subsidiary of Purdue Pharma LP, announced positive preliminary results from a phase 2 study of an investigational oral treatment for patients with insomnia during recovery from an alcohol use disorder.

Individuals with chronic sleep deprivation demonstrate a higher risk for developing systemic lupus erythematosus, with stronger effects in those with depression and bodily pain, according to data published in Arthritis Care & Research.

Biotechnology startup company Camellix has announced the discovery of a green tea-derived polyphenol molecule that may be effective in treating neurological symptoms associated with long COVID, including loss of smell and brain fog.

People with behavioral variant frontotemporal dementia were more likely to exhibit apathy and functional decline, even in the mildest stage of dementia, compared with patients with Alzheimer’s disease, researchers recently reported.

A blood-based biomarker test aided diagnosis and clinical management of Alzheimer’s disease by detecting brain amyloidosis in symptomatic patients, researchers reported at the Clinical Trials for Alzheimer’s Disease annual meeting.

With an estimated 1 billion people affected by migraine worldwide, there is an urgent need to provide effective treatment for this debilitating disease.

Clinical outcome assessments currently used for people with Lennox-Gastaut syndrome and Dravet syndrome were “not fit” for evaluating non-seizure outcomes, researchers said, prompting the development of a global clinical impression measure.